Back to Investors
Uo

University of Cambridge Enterprise Fund VIII

Venture Capital

Portfolio

1

companies


Portfolio companies

P

PharmEnable

PharmEnable develops next-generation small molecule drugs for challenging disease targets using an artificial intelligence platform.


Recent investments

Seed
£6.0M

MP Healthcare led the pre-Series A financing to help fund the expansion of the company drug discovery pipeline in oncology and neurology.

"At PharmEnable, we believe that everyone deserves safe and effective treatments, and we are committed to applying the principles chemical novelty, diversity and 3-dimensionality to design powerful new small molecule drugs."
— Hannah Sore, CEO